Impact Factor 3.566

The Frontiers in Neuroscience journal series is the 1st most cited in Neurosciences

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Neurosci. | doi: 10.3389/fnins.2018.00296

Altered serum tumor necrosis factor and interleukin-1β in first-episode drug-naive and chronic schizophrenia

  • 1Second Xiangya Hospital, Central South University, China
  • 2Guangzhou First People's Hospital, China
  • 3First Affiliated Hospital of Kunming Medical University, China
  • 4University of Texas Health Science Center at Houston, United States

Objective: Abnormality of the immune system might play a significant role in the pathogenesis of schizophrenia. We want to identity whether the serum TNF-α and IL-1β levels were changed in FEDN patients and CP and to investigate the relationship between both cytokines and psychopathological symptoms.
Methods: We recruited 69 FEDN patients, 87 CP and 61 healthy controls. Schizophrenia symptomatology was evaluated with the Positive and Negative Syndrome Scale (PANSS), the Scale for the Assessment of Negative Symptoms (SANS) and Clinical Global Impression Scale (CGI). Serum TNF-α and IL-1β levels were examined using sandwich enzyme-linked immunosorbent assay (ELISA).
Results: TNF-α and IL-1β levels in CP were significantly higher compared to healthy controls, but TNF-α and IL-1β levels in FEDN patients were significantly lower than in both CP and healthy controls. A moderate correlation between serum TNF-α or IL-1β levels and PANSS negative subscore was found in CP. But there was no correlation between altered cytokines and clinical symptoms in FEDN patients.
Conclusions: Increased TNF-α and IL-1β levels in chronic patients may be associated with the progression, psychotropic drugs or other factors occur during chronic stage. Immune modulating treatments may become a new strategy of therapy for this subgroup of patients.

Keywords: Schizophrenia, Cytokines, TNF-α, IL-1β, negative symptoms

Received: 11 Dec 2017; Accepted: 16 Apr 2018.

Edited by:

Pei Jiang, Jining Medical University, China

Reviewed by:

Luigia Trabace, University of Foggia, Italy
Luc Ver Donck, Janssen Research and Development, a Division of Janssen Pharmaceutica NV, Belgium  

Copyright: © 2018 zhu, zhang, liu, wu, guo, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Jingping Zhao, Second Xiangya Hospital, Central South University, Changsha, China, zhaojingping@csu.edu.cn